OTCBB:AGNPF

Algernon Pharmaceuticals Stock Forecast

etoro logo Buy AGNPF
*Your capital is at risk
$0.275
+0 (+0%)
At Close: Aug 10, 2026
Add AGNPF to Watchlist?
  • Easy Tracking In The Watchlist

AGNPF Performance

FAQ

What is the symbol for Algernon Pharmaceuticals Inc. Stock and on which exchange is it traded?
The symbol for Algernon Pharmaceuticals Inc. is AGNPF and it is traded on the OTCBB (OTC Bulletin Board).

Should I buy or sell Algernon Pharmaceuticals Inc. Stock?
Based on market data through Aug 10, 2026, StockInvest.us rates Algernon Pharmaceuticals Inc. (AGNPF) as Hold/Accumulate with a technical score of 0.00 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation. Since the Hold signal began on Mar 09, 2026, the price has fallen 8.09%. The current 3-month trend forecast projects a rise of 25.15%.

How to buy Algernon Pharmaceuticals Inc. Stock?
Algernon Pharmaceuticals Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Algernon Pharmaceuticals Inc. Stock.

What's the current price of Algernon Pharmaceuticals Inc. Stock?
As of the end of day on the Aug 10, 2026, the price of an Algernon Pharmaceuticals Inc. (AGNPF) share was $0.275.

What is the 52-week high and low for Algernon Pharmaceuticals Inc. Stock?
The 52-week high for Algernon Pharmaceuticals Inc. Stock is $0.640 and the 52-week low is $0.0357.

What is the market capitalization of Algernon Pharmaceuticals Inc. Stock?
As of the Aug 10, 2026, the market capitalization of Algernon Pharmaceuticals Inc. is 1.679M.

When is the next earnings date for Algernon Pharmaceuticals Inc.?
The upcoming earnings date for Algernon Pharmaceuticals Inc. is Dec 18, 2026.
Click to get the best stock tips daily for free!
ABOUT ALGERNON PHARMACEUTICALS INC.
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets N...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE